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Abstract
In leprosy, the nasal mucosa is considered as the principal route of transmission for the bacillus Mycobacterium leprae. The objective of this
study was to identify M. leprae in the oral mucosa of 50 untreated leprosy patients, including 21 paucibacillary (PB) and 29 multibacillary
(MB) patients, using immunohistochemistry (IHC), with antibodies against bacillus Calmette-Guerin (BCG) and phenolic glycolipid antigen-1
(PGL-1), and polymerase chain reaction (PCR), with MntH-specific primers for M. leprae, and to compare the results. The material was
represented by 163 paraffin blocks containing biopsy samples obtained from clinically normal sites (including the tongue, buccal mucosa and
soft palate) and visible lesions anywhere in the oral mucosa. All patients and 158 available samples were included for IHC study. Among the
161 available samples for PCR, 110 had viable DNA. There was viable DNA in at least one area of the oral mucosa for 47 patients. M. leprae
was detected in 70% and 78% of patients using IHC and PCR, respectively, and in 94% of the patients by at least one of the two diagnostic
methods. There were no differences in detection of M. leprae between MB and PB patients. Similar results were obtained using anti-BCG
and anti-PGL-1 antibodies, and immunoreactivity occurred predominantly on free-living bacteria on the epithelial surface, with a predilection
for the tongue. Conversely, there was no area of predilection according to the PCR results. M. leprae is present in the oral mucosa at a high
frequency, implicating this site as a potential means of leprosy transmission.
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Introduction
There has been a notable decline in the global prevalence of
leprosy, which has been primarily attributed to the use of
multidrug therapy. However, 130 countries and territories
submitted reports of leprosy to the World Health Organi-
zation (WHO) by the beginning of 2011, specifically from
regions in Southeast Asia, North and South America, Africa
and the Western Pacific. Worldwide, a total of 228 474 new
cases were detected in 2010, and the global registered
prevalence for the first quarter of 2011 was 192 246 cases
[1]. Early diagnosis and the appropriate treatment of
patients are the key elements for blocking disease transmis-
sion [2].
The mode of transmission of leprosy remains unclear;
however, the upper respiratory tract, particularly the nasal
mucosa, is considered as the primary route of entry and
elimination of M. leprae [2]. There have been many studies
showing the role of the nasal mucosa in the transmission of
M. leprae; however, few studies have been conducted in the
oral mucosa. Some reports indicated the participation of the
oral mucosa in leprosy transmission [2,3], particularly when
there are leprosy-specific lesions [4].
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Such lesions have been described in multibacillary (MB)
patients in advanced stages of the disease [5–8]. Paucibacillary
(PB) patients or those patients with incipient disease rarely
present lesions in the oral mucosa [9].
Recent studies have described the rarity of oral lesions in
leprosy [9–14], possibly due to the effectiveness of multidrug
therapy. However, alcohol-acid-resistant bacilli (AARB) have
been detected in the clinically normal oral mucosa of MB
patients [7,13,15–17]. Recently, M. leprae DNA was amplified
from oral mucosa samples [3,18] in MB and PB patients using
polymerase chain reaction (PCR), showing that sensitive
techniques can detect the presence of bacilli even when they
are undetectable by routine examination.
Immunohistochemistry (IHC) with antibodies that are
directed against M. leprae antigens is another sensitive tech-
nique for detecting the bacillus, and this technique preserves
tissue integrity. Among the various antibodies, anti-BCG [19]
and anti-PGL-1 [20,21] are the most widely used.
Our aim was to investigate the presence of M. leprae, using
IHC and PCR, in the oral mucosa from leprosy patients and to
compare the results from PB and MB patients, the preferred
location of the bacillus, and the efficacy of the methods in
detecting M. leprae antigens and DNA.
Methods
This was a cross-sectional retrospective study approved by the
Research Ethics Committee of S~ao Paulo Federal University
(CEP 0609/04 and amended on 10 January 2010). The study
analysed 163 oral mucosa biopsy samples included in paraffin
blocks from 50 leprosy patients before starting treatment. The
biopsy samples were systematically obtained from clinically
normal mucosa, including the buccal mucosa, soft palate and
tongue at pre-established points, totalling 150 samples, and 13
additional biopsy samples of clinically suspected leprosy-spe-
cific lesions that were noted in any part of the oral cavity.
Histopathology revealed no specific impairment of the oral
mucosa in any of the samples, excluding two normal mucosa
samples from the same MB patient in which granulomas and
AARB were evident [9,13,14].
The patient charts were reviewed, and their ages, gender and
clinical forms of leprosy according to the WHO operational
classification [22] were recorded. For inclusion in the study, the
paraffin blocks for each patient must have contained sufficient
material to generate the IHC sections and extract genomic DNA.
Immunohistochemistry
Immunohistochemistry was performed using the method of
third-generation polymers labelled with immunoglobulins and
peroxidase [23] with anti-BCG (rabbit anti-BCG, code B0124;
Dako A/Sm, Glostrup, Denmark) and anti-PGL-1 (anti-M. le-
prae produced in rabbits, Institute of Tropical Medicine,
College of Medicine, University of S~ao Paulo, Brazil) polyclonal
primary antibodies.
The microscopic analysis of immunoreactivity was per-
formed in the cytoplasms of the epithelial cells, within
macrophages and nerves in the corium and on free-living
bacteria on the epithelial surface. The presence of a brown
precipitate at the site indicated a reaction between the
antigen and the primary antibody and was considered
positive. Skin from an MB patient was used as a positive
control, and the primary antibody was omitted for the
negative control.
Polymerase chain reaction
For the PCR analysis, two 5.0-lm sections from each
sample were deparaffinised with xylene, hydrated in
decreasing concentrations of ethanol, and lysed using a
buffer (1 M Tris, pH 8.0, 0.5 M EDTA, 10% SDS, 1 M NaCl,
and sterile water) to which 500 lg/mL proteinase K was
added every 24 h for 3 day. DNA was extracted using a
4-M ammonium acetate solution and precipitated with
isopropanol. After quantification, 5.0 lL of DNA was used
per reaction.
A previously designed pair of primers that was specific to a
336-bp internal sequence of the manganese ion transporter
gene (MntH) was used to detect M. leprae bacilli, according to
a standardized protocol for PCR [24].
The specificity of these primers was confirmed using
cultured samples of Mycobacterium tuberculosis and Mycobacte-
rium avium complex, in which no amplification was detected,
thus excluding any cross-reactivity between the M. leprae
MntH primers and sequences from other mycobacteria. In
addition, 10 samples with positive PCR products for the
M. leprae MntH gene were randomly selected, and PCR was
performed using primers to amplify a 383-bp sequence for
otherMycobacterium spp., which yielded a negative result for all
of the tissue samples and positive amplification only for
cultured M. tuberculosis [24].
For all of the oral mucosa samples that yielded negative PCR
results for the M. leprae MntH gene, an additional PCR was
performed with keratin-specific primers, which amplified a
343-bp fragment, to confirm that human genomic material was
present [24].
To confirm the sequences of the PCR products that were
amplified using the M. leprae MntH primers, six samples were
sequenced, and they indicated identity and homogeneity to a
M. leprae MntH gene sequence in GenBank (AL583924 and GI:
13093618).
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Statistical analysis
The chi-squared test, Cochran-Mantel–Haenszel test and
Fisher’s exact test were used to evaluate the associations
between variables, depending on the nature of the data. An
analysis of variance was used to determine significant differ-
ences between the groups. The agreement between methods
was assessed using a kappa analysis. The kappa values were
interpreted as follows: <0, no agreement; 0–0.19, poor
agreement; 0.20–0.39, fair agreement; 0.40–0.59, moderate
agreement; 0.60–0.79, substantial agreement; 0.80–1.00,
almost perfect agreement. The minimum level of significance
considered was 5%.
Results
The sample consisted of 50 leprosy patients, 26 (52%) women
and 24 (48%) men, with a mean age of 53 years (range, 18–84).
According to WHO operational classification [22], 29 (58%)
were MB and 21 (42%) were PB. There was no association
between gender (p 0.96) or age (p 0.67) and MB or PB patients.
Immunohistochemistry
Fifty patients were included in the IHC study, which resulted in
158/163 samples that contained sufficient material to generate
the IHC sections (49 soft palate samples, 49 buccal mucosa
samples, 48 tongue samples and 12 samples from other areas
of the oral mucosa).
Overall, 70% (35/50) of the patients were positive in at least
one sample, 68% (34/50) using anti-BCG antibodies and 66%
(33/50) using anti-PGL-1 antibodies, demonstrating a strong
agreement between the results obtained with the two
antibodies (p <0.0001). However, there were no significant
differences between the PB (80.95%, 17/21) and MB (62.07%,
18/29) patients and IHC positivity, including both anti-BCG and
anti-PGL-1 antibodies (Table 1).
Using anti-BCG and anti-PGL-1 antibodies, regarding the
areas of the oral mucosa, antigens were more frequently
detected in the tongue (62.5%, 30/48) than in the soft palate
(10.2%, 5/49; p <0.0001), the buccal mucosa (16.3%, 8/49;
p <0.0001) and the other areas of the oral mucosa (25%, 3/12;
p 0.04).
There was an irregular distribution of antigens in the tissue
samples (Fig. 1). Including both antibodies, 50% (25/50) of the
patients showed immunoreactivity on free-living bacteria on
the epithelial surface compared with 14% (7/50) within
macrophages in the corium (p 0.0003) and 22% (11/50) in
the nerve (p 0.006). Notably, nerves were visible histologically
in only 27 samples taken from 19 patients in previous studies
performed on the same material [9,13,14]. No reactivity was
observed within the cytoplasm of epithelial cells.
Regarding tissue distribution among the areas of the oral
mucosa, higher immunoreactivity was observed on free-living
bacteria on the epithelial surface (50%, 25/50) of the tongue
than on the soft palate (6%, 3/50) and the buccal mucosa
samples (0/50; p <0.0001). There was no significant association
between immunoreactivity within macrophages in the corium
and areas of the oral mucosa (p 0.66). Immunoreactivity within
macrophages in the corium was observed in 8% (4/50) of the
soft palate samples, 6% (3/50) of the tongue samples and 2% (1/
50) of the buccal mucosa samples.
Polymerase chain reaction
This analysis included 161/163 samples that contained suffi-
cient material to extract genomic DNA; however, only 110
samples had viable DNA. There was viable DNA in at least one
area of the oral mucosa for 47 patients. Among these patients,
82.98% (39/47) yielded positive PCR results for the MntH gene
in at least one sample. Taking into account all patients, the
positivity was 78% (39/50; Table 1). Representative PCR
results are shown in Fig. 2. The samples from three patients
who did not have viable DNA indicated IHC positivity.
TABLE 1. Sensitivity of immunohis-
tochemistry results for anti-BCG
and anti-PGL-1 antibodies and PCR
for the MntH gene in 50 leprosy
patients according to clinical form
Method
Positive results
Total leprosy
patients (n = 50)
N (%)
Multibacillary
patients (n = 29)
N (%)
Paucibacillary
patients (n = 21)
N (%) p value
Immunohistochemistry
anti-PGL-1 antibody
33 (66) 18 (62.06) 15 (71.43) 0.69
Immunohistochemistry
anti-BCG antibody
34 (68) 17 (58.62) 17 (80.95) 0.17
PCR - MntH gene 39 (78) 25 (86.20) 14 (66.66) 0.19
Immunohistochemistry
(anti-BCG and/or anti-PGL-1
antibodies) and/or PCR-MntH
gene
47 (94) 26 (89.65) 21 (100) 0.35
N, number of patients.
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Regarding the clinical forms of the disease, there were no
significant differences between the MB (86.20%, 25/29) and PB
(66.66%, 14/21) patients and PCR for the MntH gene positivity
(Table 1).
The distribution of the frequencies of positive PCR results
in all areas of the oral mucosa was similar: 69.7% (23/33) in the
soft palate samples, 60.61% (20/33) in the tongue samples,
69.45% (25/36) in the buccal mucosa samples and 62.5% (5/8)
in the other areas.
IHC and PCR
Considering both the IHC and PCR methods, 94% (47/50) of
the patients were positive in one or more areas of the oral
mucosa using at least one method: 26% (13/50) were positive
in one area, 32% (16/50) in two areas, 34% (17/50) in three
areas, and 2% (1/50) in four areas.
To evaluate the agreement between the results for the
methods, only the 110 samples that were validated for PCR
were considered, and 40.91% (45/110) of the samples showed
agreement between IHC and PCR methods. The kappa
statistics for the results between PCR and anti-BCG antibodies
and anti-PGL-1 antibodies resulted in <0 and no agreement,
respectively. The kappa statistics for the results between
anti-BCG and anti-PGL-1 in 110 samples indicated almost
perfect agreement (j = 0.969; 95% CI, 0.782 to >1.0). No
significant differences were found between IHC and PCR
methods in the PB or MB patients.
Discussion
To the best of our knowledge, this is the first molecular and
immunological study of M. leprae using oral mucosa biopsy
material from leprosy patients. The results suggest that the
oral mucosa is an important source of bacilli. This observation
(a) (b)
(c) (d)
FIG. 1. (a) and (c) Immunoreactivity of free bacteria (granular form) on the epithelial surface of the tongue. (b) and (d) Immunoreactivity in the
cytoplasm of macrophages found in the corium of the soft palate (4009) (a, b, BCG marker; c, d, PGL-1 marker).
FIG. 2. Agarose gel electrophoresis of PCR products obtained with
primers that amplified a MntH gene fragment (336 bp) to identify
Mycobacterium leprae. 2–11: Oral mucosa biopsy samples of leprosy
patients. Note the positive results and the specificity of samples 2, 5, 6,
7, 9, 10 and 11. 1: Negative control (no DNA added). 12:
Mycobacterium avium complex. 13: Mycobacterium tuberculosis. 14:
Positive control (plasmid that contained the cloned MntH gene of
Mycobacterium leprae). 15: 100-bp marker.
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was reported in 2011 by Martinez et al. [3], who employed
PCR with primers that amplified a 130-bp fragment in the
RLEP3 genomic region of M. leprae and detected bacillus DNA
in swabs of the buccal mucosa in 18.26% of the patients.
The higher rate of positivity found for PCR in this study in
relation to IHC was expected because PCR is considered the
reference standard method for detecting microorganisms [25].
However, an unexpected result was the high frequency of
positive results obtained by both methods for PB patients, not
significantly different from the frequency rates obtained for MB
patients, a phenomenon also observed by Martinez et al. [3].
This finding is not consistent with reports in the literature,
which uniformly suggest a greater involvement of the oral
mucosa in MB patients [4–9,13,15]. It is likely that PCR and
IHC, highly sensitive techniques, are able to demonstrate the
presence of bacilli, even in minimal amounts, and this possibly
occurs in the oral mucosa of PB patients.
In previous clinical studies, several authors have claimed
that the soft palate [5,6] and the hard palate [7,8] are the
preferred areas of M. leprae in the oral mucosa. In this study,
bacillus DNA was amplified from all three areas at similar
frequencies using PCR. This result may be explained by the
possibility of cross-contamination, because the biopsies were
performed using the same surgical instruments in each patient,
because the material was originally obtained for previous
histopathological studies [9,13,14]. Conversely, the IHC
results using anti-PGL-1 and anti-BCG antibodies indicate a
predilection for the tongue.
The presence of M. leprae on the epithelial surface of oral
leprosy lesions has been reported in histopathological exam-
inations [8,16,17]; however, its prevalence on free-living
bacteria on the epithelial surface of clinically normal mucosa,
as shown using IHC, was not reported previously. Possible
explanations may include contamination by nasal secretions
that contain the bacilli or penetration by the bacilli via the oral
mucosa. Thus, the oral mucosa may act as an entry point for
M. leprae, which has previously been proposed [3].
Therefore, despite the lower rate of positivity reported by
Martinez et al. (18%), compared with this study, further
epidemiological studies designed to investigate M. leprae in
the oral mucosa should collect material with swabs, a
technique that is less invasive and more easily performed than
biopsies. However, swabs on the tongue (and not on the
buccal mucosa as performed by the aforementioned research-
ers) may increase the likelihood of finding the bacillus. It would
be interesting to conduct future research for PCR detection of
M. leprae using swabs taken from the nasal mucosa and tongue,
in order to compare the positivity rates between the two sites,
because the nasal mucosa is considered the major port of
entry and exit of bacilli.
There are some limitations regarding the present study:
retrospective design, absence of healthy controls of the same
population and, in particular, possible cross-contamination
during the collection of surgical biopsy samples from different
locations of the oral mucosa for all the PCR results. On the
other hand, although anti-BCG antibodies react with Myco-
bacteria sp. antigens, results are validated by comparison and
strong concordance with anti-PGL-1 antibodies, which react
specifically with M. leprae antigens.
The high rate of positivity for M. leprae found in the studied
patients demonstrates the epidemiological importance of the
oral mucosa in the transmission of leprosy, suggesting that
bacilli can be secreted in the saliva and transmitted to other
individuals. Thus, investigating M. leprae in oral mucosa or
saliva samples by PCR may represent an alternative for
detecting infected individuals in populations at risk, particularly
those who have had contact with leprosy patients. However,
the presence of M. leprae in the oral mucosa without the
occurrence of recognizable clinical signs or symptoms is not
synonymous with leprosy infection and may simply represent a
transient contamination process in the oral cavity.
In conclusion, we suggest that M. leprae is present in the
oral mucosa of leprosy patients at high frequencies and that
both MB and PB patients have M. leprae in their oral mucosa at
similar frequencies. IHC indicates that the tongue is the site in
the oral mucosa at which M. leprae is more likely to be found,
particularly on free-living bacteria on epithelial surfaces, and
both anti-BCG and anti-PGL-1 antibodies give similar results.
PCR is more effective than IHC in detecting M. leprae in the
oral mucosa.
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